Literature DB >> 28839864

Autoimmune liver disease: evaluating overlapping and cross-over presentations-a case-based discussion.

Margaret Corrigan1,2, Gideon M Hirschfield1,2.   

Abstract

The three classic autoimmune liver diseases are recognised based on identifying varying clinical, laboratory, histological and radiological features that collectively classify patients. In the absence of defined aetiological factors, it is recognised that disease spectrum is broad, and, in this context, it is not infrequent for disease boundaries to be blurred, leading to overlapping features that may be present at the time of diagnosis or may appear later in the course of disease. Given the absence of accepted diagnostic criteria for overlap/cross-over syndromes, alongside weak data for intervention, it is recommended that a multidisciplinary, patient-specific approach be used to establish individual treatment pathways.

Entities:  

Keywords:  AUTOIMMUNE BILIARY DISEASE; AUTOIMMUNE HEPATITIS; PRIMARY BILIARY CIRRHOSIS

Year:  2016        PMID: 28839864      PMCID: PMC5369510          DOI: 10.1136/flgastro-2016-100698

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  12 in total

Review 1.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

2.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

Authors: 
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

3.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

4.  Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.

Authors:  Minoru Nakamura; Hisayoshi Kondo; Tsuyoshi Mori; Atsumasa Komori; Mutsumi Matsuyama; Masahiro Ito; Yasushi Takii; Makiko Koyabu; Terufumi Yokoyama; Kiyoshi Migita; Manabu Daikoku; Seigo Abiru; Hiroshi Yatsuhashi; Eiichi Takezaki; Naohiko Masaki; Kazuhiro Sugi; Koichi Honda; Hiroshi Adachi; Hidehiro Nishi; Yukio Watanabe; Yoko Nakamura; Masaaki Shimada; Tatsuji Komatsu; Akira Saito; Takeo Saoshiro; Hideharu Harada; Takeshi Sodeyama; Shigeki Hayashi; Akihide Masumoto; Takehiro Sando; Tetsuo Yamamoto; Hironori Sakai; Masakazu Kobayashi; Toyokichi Muro; Michiaki Koga; Zakera Shums; Gary L Norman; Hiromi Ishibashi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

Review 5.  Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue.

Authors:  Kirsten Muri Boberg; Roger W Chapman; Gideon M Hirschfield; Ansgar W Lohse; Michael P Manns; Erik Schrumpf
Journal:  J Hepatol       Date:  2010-09-18       Impact factor: 25.083

6.  Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.

Authors:  Marco Carbone; George F Mells; Greta Pells; Muhammad F Dawwas; Julia L Newton; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones
Journal:  Gastroenterology       Date:  2012-12-12       Impact factor: 22.682

7.  Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.

Authors:  P Michieletti; I R Wanless; A Katz; P J Scheuer; S J Yeaman; M F Bassendine; J M Palmer; E J Heathcote
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

8.  Frequency and nature of the variant syndromes of autoimmune liver disease.

Authors:  A J Czaja
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

9.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Authors:  Gideon M Hirschfield; Andrew Mason; Velimir Luketic; Keith Lindor; Stuart C Gordon; Marlyn Mayo; Kris V Kowdley; Catherine Vincent; Henry C Bodhenheimer; Albert Parés; Michael Trauner; Hanns-Ulrich Marschall; Luciano Adorini; Cathi Sciacca; Tessa Beecher-Jones; Erin Castelloe; Olaf Böhm; David Shapiro
Journal:  Gastroenterology       Date:  2014-12-11       Impact factor: 22.682

Review 10.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.